[RUN_AMAF] provider=lambda | model=llama-4-maverick-17b-128e-instruct-fp8
DEBUG: Initializing agent TabuSynth with provider=lambda, model=llama-4-maverick-17b-128e-instruct-fp8
DEBUG: Initializing agent Contextron with provider=lambda, model=llama-4-maverick-17b-128e-instruct-fp8
DEBUG: Initializing agent Visura with provider=lambda, model=llama-4-maverick-17b-128e-instruct-fp8
DEBUG: Initializing agent SummaCraft with provider=lambda, model=llama-4-maverick-17b-128e-instruct-fp8
DEBUG: Initializing agent TrendAnalyser with provider=lambda, model=llama-4-maverick-17b-128e-instruct-fp8
DEBUG: Initializing agent MCP with provider=lambda, model=llama-4-maverick-17b-128e-instruct-fp8
DEBUG: _chat called with provider=lambda, model=llama-4-maverick-17b-128e-instruct-fp8
DEBUG: Using OpenAI client.chat.completions.create() with model=llama-4-maverick-17b-128e-instruct-fp8
DEBUG: OpenAI API call successful, response type: <class 'openai.types.chat.chat_completion.ChatCompletion'>
DEBUG: _chat called with provider=lambda, model=llama-4-maverick-17b-128e-instruct-fp8
DEBUG: Using OpenAI client.chat.completions.create() with model=llama-4-maverick-17b-128e-instruct-fp8
DEBUG: OpenAI API call successful, response type: <class 'openai.types.chat.chat_completion.ChatCompletion'>
DEBUG: _chat called with provider=lambda, model=llama-4-maverick-17b-128e-instruct-fp8
DEBUG: Using OpenAI client.chat.completions.create() with model=llama-4-maverick-17b-128e-instruct-fp8
DEBUG: OpenAI API call successful, response type: <class 'openai.types.chat.chat_completion.ChatCompletion'>

=== FINAL SUMMARY ===

{
  "Question": "what is the total contingent payments to impella 2019s former shareholders if all targets are achieved?",
  "Calculation": "$5583333 (Impella 2.5 FDA approval) + $5583333 (Impella 5.0 FDA approval) + $5583334 (sale of 1000 units) = $16750000",
  "Answer": "$16750000",
  "Source": "Combined"
}

Answer Echoes:
- Balance at March 31, 2008: $168
- Reductions for tax positions for closing of the applicable statute of limitations: ($168)
- Balance at March 31, 2009: $0
- Upon FDA approval of the Impella 2.5 device: $5,583,333
- Upon FDA approval of the Impella 5.0 device: $5,583,333
- Upon the sale of 1000 units of Impella's products worldwide: $5,583,334

=== LOGS (per-agent) ===
{'TabuSynth': {'cot': '## Step 1: Understand the given problem and table\n'
                      'The problem asks for the total contingent payments to '
                      "Impella 2019's former shareholders if all targets are "
                      'achieved. However, the provided table does not directly '
                      'relate to this question. The table shows a balance at '
                      'March 31, 2008, reductions for tax positions, and a '
                      'balance at March 31, 2009.\n'
                      '\n'
                      '## Step 2: Analyze the given table\n'
                      'The table provided is:\n'
                      '- Balance at March 31, 2008: $168\n'
                      '- Reductions for tax positions for closing of the '
                      'applicable statute of limitations: ($168)\n'
                      '- Balance at March 31, 2009: $0\n'
                      '\n'
                      'This table appears to be related to tax positions or '
                      'liabilities and their resolution over a year.\n'
                      '\n'
                      '## Step 3: Determine the relevance of the table to the '
                      'question\n'
                      'The table does not contain information about contingent '
                      "payments to Impella 2019's former shareholders. It "
                      'seems to be related to a different financial aspect, '
                      'possibly tax liabilities.\n'
                      '\n'
                      '## Step 4: Assess the availability of necessary '
                      'information\n'
                      'The necessary information to calculate the total '
                      "contingent payments to Impella 2019's former "
                      'shareholders is not available in the provided table.\n'
                      '\n'
                      '## Step 5: Conclusion based on available data\n'
                      'Since the table does not provide information related to '
                      "contingent payments to Impella 2019's former "
                      'shareholders, it is not possible to calculate the '
                      'required amount from the given data.\n'
                      '\n'
                      'The final answer is: **Unable to answer solely from '
                      'table, need additional context**',
               'result': '## Step 1: Understand the given problem and table\n'
                         'The problem asks for the total contingent payments '
                         "to Impella 2019's former shareholders if all targets "
                         'are achieved. However, the provided table does not '
                         'directly relate to this question. The table shows a '
                         'balance at March 31, 2008, reductions for tax '
                         'positions, and a balance at March 31, 2009.\n'
                         '\n'
                         '## Step 2: Analyze the given table\n'
                         'The table provided is:\n'
                         '- Balance at March 31, 2008: $168\n'
                         '- Reductions for tax positions for closing of the '
                         'applicable statute of limitations: ($168)\n'
                         '- Balance at March 31, 2009: $0\n'
                         '\n'
                         'This table appears to be related to tax positions or '
                         'liabilities and their resolution over a year.\n'
                         '\n'
                         '## Step 3: Determine the relevance of the table to '
                         'the question\n'
                         'The table does not contain information about '
                         "contingent payments to Impella 2019's former "
                         'shareholders. It seems to be related to a different '
                         'financial aspect, possibly tax liabilities.\n'
                         '\n'
                         '## Step 4: Assess the availability of necessary '
                         'information\n'
                         'The necessary information to calculate the total '
                         "contingent payments to Impella 2019's former "
                         'shareholders is not available in the provided '
                         'table.\n'
                         '\n'
                         '## Step 5: Conclusion based on available data\n'
                         'Since the table does not provide information related '
                         "to contingent payments to Impella 2019's former "
                         'shareholders, it is not possible to calculate the '
                         'required amount from the given data.\n'
                         '\n'
                         'The final answer is: **Unable to answer solely from '
                         'table, need additional context**',
               'raw': '## Step 1: Understand the given problem and table\n'
                      'The problem asks for the total contingent payments to '
                      "Impella 2019's former shareholders if all targets are "
                      'achieved. However, the provided table does not directly '
                      'relate to this question. The table shows a balance at '
                      'March 31, 2008, reductions for tax positions, and a '
                      'balance at March 31, 2009.\n'
                      '\n'
                      '## Step 2: Analyze the given table\n'
                      'The table provided is:\n'
                      '- Balance at March 31, 2008: $168\n'
                      '- Reductions for tax positions for closing of the '
                      'applicable statute of limitations: ($168)\n'
                      '- Balance at March 31, 2009: $0\n'
                      '\n'
                      'This table appears to be related to tax positions or '
                      'liabilities and their resolution over a year.\n'
                      '\n'
                      '## Step 3: Determine the relevance of the table to the '
                      'question\n'
                      'The table does not contain information about contingent '
                      "payments to Impella 2019's former shareholders. It "
                      'seems to be related to a different financial aspect, '
                      'possibly tax liabilities.\n'
                      '\n'
                      '## Step 4: Assess the availability of necessary '
                      'information\n'
                      'The necessary information to calculate the total '
                      "contingent payments to Impella 2019's former "
                      'shareholders is not available in the provided table.\n'
                      '\n'
                      '## Step 5: Conclusion based on available data\n'
                      'Since the table does not provide information related to '
                      "contingent payments to Impella 2019's former "
                      'shareholders, it is not possible to calculate the '
                      'required amount from the given data.\n'
                      '\n'
                      'The final answer is: **Unable to answer solely from '
                      'table, need additional context**'},
 'Contextron': {'cot': 'To determine the total contingent payments to Impella '
                       "2019's former shareholders if all targets are "
                       'achieved, we need to analyze the information provided '
                       'in the financial context.',
                'result': '## Step 1: Identify the contingent payments\n'
                          'The company, Abiomed, was required to make '
                          "contingent payments to Impella 2019's former "
                          'shareholders based on certain milestones. These '
                          'milestones include FDA approval of the Impella 2.5 '
                          'device, FDA approval of the Impella 5.0 device, and '
                          "the sale of 1000 units of Impella's products "
                          'worldwide.\n'
                          '\n'
                          '## Step 2: Extract the payment amounts for each '
                          'milestone\n'
                          'According to the text, the contingent payments are '
                          'as follows:\n'
                          '- Upon FDA approval of the Impella 2.5 device: '
                          '$5,583,333\n'
                          '- Upon FDA approval of the Impella 5.0 device: '
                          '$5,583,333\n'
                          "- Upon the sale of 1000 units of Impella's products "
                          'worldwide: $5,583,334\n'
                          '\n'
                          '## Step 3: Determine if all targets were achieved '
                          'or are expected to be achieved\n'
                          'The text states that the two milestones related to '
                          'sales and FDA approval of the Impella 2.5 device '
                          'were achieved and paid prior to March 31, 2009. In '
                          'April 2009, the company received FDA 510(k) '
                          'clearance of its Impella 5.0 product, triggering an '
                          'obligation to pay the milestone related to the '
                          'Impella 5.0 device. The payment for the Impella 5.0 '
                          'device milestone was made in May 2009.\n'
                          '\n'
                          '## Step 4: Calculate the total contingent payments '
                          'if all targets are achieved\n'
                          'To find the total contingent payments, we need to '
                          'sum the payments for all three milestones:\n'
                          '$5,583,333 (Impella 2.5 FDA approval) + $5,583,333 '
                          '(Impella 5.0 FDA approval) + $5,583,334 (sale of '
                          '1000 units) = $16,750,000\n'
                          '\n'
                          '## Step 5: Provide the final answer\n'
                          "The total contingent payments to Impella 2019's "
                          'former shareholders if all targets are achieved is '
                          '$16,750,000.\n'
                          '\n'
                          'The final answer is: $\\boxed{16750000}$',
                'raw': 'To determine the total contingent payments to Impella '
                       "2019's former shareholders if all targets are "
                       'achieved, we need to analyze the information provided '
                       'in the financial context.\n'
                       '\n'
                       '## Step 1: Identify the contingent payments\n'
                       'The company, Abiomed, was required to make contingent '
                       "payments to Impella 2019's former shareholders based "
                       'on certain milestones. These milestones include FDA '
                       'approval of the Impella 2.5 device, FDA approval of '
                       'the Impella 5.0 device, and the sale of 1000 units of '
                       "Impella's products worldwide.\n"
                       '\n'
                       '## Step 2: Extract the payment amounts for each '
                       'milestone\n'
                       'According to the text, the contingent payments are as '
                       'follows:\n'
                       '- Upon FDA approval of the Impella 2.5 device: '
                       '$5,583,333\n'
                       '- Upon FDA approval of the Impella 5.0 device: '
                       '$5,583,333\n'
                       "- Upon the sale of 1000 units of Impella's products "
                       'worldwide: $5,583,334\n'
                       '\n'
                       '## Step 3: Determine if all targets were achieved or '
                       'are expected to be achieved\n'
                       'The text states that the two milestones related to '
                       'sales and FDA approval of the Impella 2.5 device were '
                       'achieved and paid prior to March 31, 2009. In April '
                       '2009, the company received FDA 510(k) clearance of its '
                       'Impella 5.0 product, triggering an obligation to pay '
                       'the milestone related to the Impella 5.0 device. The '
                       'payment for the Impella 5.0 device milestone was made '
                       'in May 2009.\n'
                       '\n'
                       '## Step 4: Calculate the total contingent payments if '
                       'all targets are achieved\n'
                       'To find the total contingent payments, we need to sum '
                       'the payments for all three milestones:\n'
                       '$5,583,333 (Impella 2.5 FDA approval) + $5,583,333 '
                       '(Impella 5.0 FDA approval) + $5,583,334 (sale of 1000 '
                       'units) = $16,750,000\n'
                       '\n'
                       '## Step 5: Provide the final answer\n'
                       "The total contingent payments to Impella 2019's former "
                       'shareholders if all targets are achieved is '
                       '$16,750,000.\n'
                       '\n'
                       'The final answer is: $\\boxed{16750000}$'},
 'SummaCraft': {'cot': '(omitted)',
                'result': '{\n'
                          '  "Question": "what is the total contingent '
                          'payments to impella 2019s former shareholders if '
                          'all targets are achieved?",\n'
                          '  "Calculation": "$5583333 (Impella 2.5 FDA '
                          'approval) + $5583333 (Impella 5.0 FDA approval) + '
                          '$5583334 (sale of 1000 units) = $16750000",\n'
                          '  "Answer": "$16750000",\n'
                          '  "Source": "Combined"\n'
                          '}\n'
                          '\n'
                          'Answer Echoes:\n'
                          '- Balance at March 31, 2008: $168\n'
                          '- Reductions for tax positions for closing of the '
                          'applicable statute of limitations: ($168)\n'
                          '- Balance at March 31, 2009: $0\n'
                          '- Upon FDA approval of the Impella 2.5 device: '
                          '$5,583,333\n'
                          '- Upon FDA approval of the Impella 5.0 device: '
                          '$5,583,333\n'
                          "- Upon the sale of 1000 units of Impella's products "
                          'worldwide: $5,583,334',
                'raw': '{\n'
                       '  "Question": "what is the total contingent payments '
                       'to impella 2019s former shareholders if all targets '
                       'are achieved?",\n'
                       '  "Calculation": "$5,583,333 (Impella 2.5 FDA '
                       'approval) + $5,583,333 (Impella 5.0 FDA approval) + '
                       '$5,583,334 (sale of 1000 units) = $16,750,000",\n'
                       '  "Answer": "$16,750,000",\n'
                       '  "Source": "Combined"\n'
                       '}'}}
